Prevalence and clinicopathological features of human epidermal growth factor receptor-2–low breast cancers: A single-center experience
Objective Human epidermal growth factor receptor-2–low breast cancer, characterized by low-level human epidermal growth factor receptor-2 expression and immunohistochemistry score 1+ or immunohistochemistry score 2+ without amplification, has been proposed as a distinct subgroup. This study investig...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-05-01
|
| Series: | Journal of International Medical Research |
| Online Access: | https://doi.org/10.1177/03000605251342508 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850151626496540672 |
|---|---|
| author | ılkay Cinar |
| author_facet | ılkay Cinar |
| author_sort | ılkay Cinar |
| collection | DOAJ |
| description | Objective Human epidermal growth factor receptor-2–low breast cancer, characterized by low-level human epidermal growth factor receptor-2 expression and immunohistochemistry score 1+ or immunohistochemistry score 2+ without amplification, has been proposed as a distinct subgroup. This study investigated the prevalence and clinicopathological characteristics of human epidermal growth factor receptor-2–low breast cancers. Methods A retrospective observational cohort study was conducted on patients diagnosed with invasive breast carcinoma between 2021 and 2023 at a single tertiary center. Data on histological type, tumor grade, human epidermal growth factor receptor-2 status, and Ki-67 proliferation index were collected. Results Among the 181 patients who were included, 54.7% were classified as human epidermal growth factor receptor-2–low, 27.6% as human epidermal growth factor receptor-2–negative, and 17.7% as human epidermal growth factor receptor-2–positive. Human epidermal growth factor receptor-2–low tumors were predominantly those classified into grade 2 (69.7%). The mean age of patients with human epidermal growth factor receptor-2–low tumors was 60 years. The Ki-67 index was significantly lower in human epidermal growth factor receptor-2–low tumors than in human epidermal growth factor receptor-2–positive and human epidermal growth factor receptor-2–negative groups (p = 0.001). No significant differences were observed in the rates of axillary lymph node metastasis among the groups (p = 0.13). Conclusion Human epidermal growth factor receptor-2–low breast cancers constitute a significant proportion of breast cancer cases and are associated with distinct clinicopathological features, including high estrogen reception positivity and lower Ki-67 proliferation rates. |
| format | Article |
| id | doaj-art-38f319262f524cff8e751cfb3cee5c26 |
| institution | OA Journals |
| issn | 1473-2300 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Journal of International Medical Research |
| spelling | doaj-art-38f319262f524cff8e751cfb3cee5c262025-08-20T02:26:10ZengSAGE PublishingJournal of International Medical Research1473-23002025-05-015310.1177/03000605251342508Prevalence and clinicopathological features of human epidermal growth factor receptor-2–low breast cancers: A single-center experienceılkay CinarObjective Human epidermal growth factor receptor-2–low breast cancer, characterized by low-level human epidermal growth factor receptor-2 expression and immunohistochemistry score 1+ or immunohistochemistry score 2+ without amplification, has been proposed as a distinct subgroup. This study investigated the prevalence and clinicopathological characteristics of human epidermal growth factor receptor-2–low breast cancers. Methods A retrospective observational cohort study was conducted on patients diagnosed with invasive breast carcinoma between 2021 and 2023 at a single tertiary center. Data on histological type, tumor grade, human epidermal growth factor receptor-2 status, and Ki-67 proliferation index were collected. Results Among the 181 patients who were included, 54.7% were classified as human epidermal growth factor receptor-2–low, 27.6% as human epidermal growth factor receptor-2–negative, and 17.7% as human epidermal growth factor receptor-2–positive. Human epidermal growth factor receptor-2–low tumors were predominantly those classified into grade 2 (69.7%). The mean age of patients with human epidermal growth factor receptor-2–low tumors was 60 years. The Ki-67 index was significantly lower in human epidermal growth factor receptor-2–low tumors than in human epidermal growth factor receptor-2–positive and human epidermal growth factor receptor-2–negative groups (p = 0.001). No significant differences were observed in the rates of axillary lymph node metastasis among the groups (p = 0.13). Conclusion Human epidermal growth factor receptor-2–low breast cancers constitute a significant proportion of breast cancer cases and are associated with distinct clinicopathological features, including high estrogen reception positivity and lower Ki-67 proliferation rates.https://doi.org/10.1177/03000605251342508 |
| spellingShingle | ılkay Cinar Prevalence and clinicopathological features of human epidermal growth factor receptor-2–low breast cancers: A single-center experience Journal of International Medical Research |
| title | Prevalence and clinicopathological features of human epidermal growth factor receptor-2–low breast cancers: A single-center experience |
| title_full | Prevalence and clinicopathological features of human epidermal growth factor receptor-2–low breast cancers: A single-center experience |
| title_fullStr | Prevalence and clinicopathological features of human epidermal growth factor receptor-2–low breast cancers: A single-center experience |
| title_full_unstemmed | Prevalence and clinicopathological features of human epidermal growth factor receptor-2–low breast cancers: A single-center experience |
| title_short | Prevalence and clinicopathological features of human epidermal growth factor receptor-2–low breast cancers: A single-center experience |
| title_sort | prevalence and clinicopathological features of human epidermal growth factor receptor 2 low breast cancers a single center experience |
| url | https://doi.org/10.1177/03000605251342508 |
| work_keys_str_mv | AT ılkaycinar prevalenceandclinicopathologicalfeaturesofhumanepidermalgrowthfactorreceptor2lowbreastcancersasinglecenterexperience |